Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Chandrakasan, S; Jordan, MB; Baker, A; Behrens, EM; Bhatla, D; Chien, M; Eckstein, OS; Henry, MM; Hermiston, ML; Hinson, AP; Walkovich, KJ; Yee, JD; Zoref-Lorenz, A; Allen, CE. Blood Advances. 2024; 8:2248-2258.

COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report. McDonnell, J; Cousins, K; Younger, ME M; Lane, A; Abolhassani, H; Abraham, RS; Al-Tamemi, S; Aldave-Becerra, JC; Al-Faris, EH; Alfaro-Murillo, A; Lim, XR; Lopes, JP; López, AL; Tarquini, L. Journal of Clinical Immunology. 2024; 44:86.

68 LRBA dysfunction: a new diagnostic entity caused by biallelic LRBA missense variants results in reduced CTLA-4 expression and autoimmunity. Chiang, S; Murguia-Favela, L; Wright, N; Steele, M; Seroogy, C; Blanchard-Rohner, G; Shrikhande, A; Wilson, J; Yang, L; Owsley, E; Derfalvi, B; Brager, R; Jordan, M; Marwaha, A. Clinical Immunology. 2024; 262:110010.

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Cournoyer, E; Ferrell, J; Sharp, S; Ray, A; Jordan, M; Dandoy, C; Grimley, M; Roy, S; Lorsbach, R; Merrow, AC; Nelson, A; Bartlett, A; Picarsic, J; Kumar, A. Haematologica: the hematology journal. 2024; 109:1137-1148.

Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation. Böhm, S; Wustrau, K; Pachlopnik Schmid, J; Prader, S; Ahlmann, M; Yacobovich, J; Beier, R; Speckmann, C; Behnisch, W; Ifversen, M; Lindemans, C; Henter, JI; Lehmberg, K; Ehl, S. Blood. 2024; 143:872-881.

Hemophagocytic lymphohistiocytosis: A disorder of T cell activation, immune regulation, and distinctive immunopathology. Jordan, MB. Immunological Reviews. 2024; 322:339-350.

Emapalumab Therapy Prior to Hematopoietic Stem Cell Transplant Is Associated with Improved Long-Term Chimerism and Event-Free Survival in Pediatric Patients with Hemophagocytic Lymphohistiocytosis. Verkamp, B; Jodele, S; Marsh, RA; Sabulski, DA; Davies, SM; Jordan, MB. Transplantation and Cellular Therapy. 2024; 30:s93.

Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Jordan, MB; Locatelli, F. Pediatric Blood and Cancer. 2024; 71:e30778.

Hemophagocytic Lymphohistiocytosis in the Context of Hematological Malignancies and Solid Tumors. Zoref-Lorenz, A; Lehmberg, K; Jordan, M. Advances in Experimental Medicine and Biology. 2024; 1448:429-440.

Here be dragons: A universal profile of recent T-cell (hyper)activation?. Jordan, MB. Journal of Allergy and Clinical Immunology. 2024; 153:98-99.